World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
109
Citations
37774
World Ranking
5829
National Ranking
3128

Ian F. Pollack publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ian F. Pollack sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 698 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ian F. Pollack D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ian F. Pollack sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 109 D-Index — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Ian F. Pollack is affiliated with the University of Pittsburgh in the United States and has contributed extensively to research in medicine, with a focus on genetics and molecular biology. Their work spans several subfields including genetics, molecular biology, neurology, cellular and molecular neuroscience, and pediatrics, perinatology, and child health.

Their research topics primarily cover glioma diagnosis and treatment, cerebrospinal fluid and hydrocephalus, chromatin remodeling and cancer, neuroblastoma research and treatments, spinal dysraphism and malformations, fetal and pediatric neurological disorders, and craniofacial disorders and treatments.

Ian F. Pollack has published in prominent venues, frequently contributing to:

  • Neuro-Oncology
  • Journal of Neurosurgery Pediatrics
  • Journal of Clinical Oncology
  • Nature Cancer
  • Cancers

Notable recent papers include:

  • Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children's Oncology Group Trial ACNS0333, 2020, Journal of Clinical Oncology
  • Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma, 2021, Journal of Clinical Oncology
  • Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma, 2021, JAMA Oncology
  • Failure of human rhombic lip differentiation underlies medulloblastoma formation, 2022, Nature
  • Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma, 2021, Journal of Clinical Investigation

The scientist works frequently with several co-authors, including:

  • Sameer Agnihotri
  • John R. W. Kestle
  • Gary Kohanbash
  • Baoli Hu
  • Mandeep S. Tamber

Ian F. Pollack's awards include membership in the Association of American Physicians. Their publication record consists of over 168 papers in medicine and 87 in biochemistry, genetics, and molecular biology, reflecting a sustained focus on pediatric neurological disorders and cancer-related research.

Best Publications

  • Subgroup-specific structural variation across 1,000 medulloblastoma genomes

    Paul A. Northcott;Paul A. Northcott;David J.H. Shih;John Peacock;Livia Garzia

  • Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.

    Hideho Okada;Pawel Kalinski;Ryo Ueda;Aki Hoji

  • Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.

    A Soeda;M Park;D Lee;A Mintz

  • Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

    Hideho Okada;Michael Weller;Raymond Huang;Gaetano Finocchiaro

  • Brain Tumors in Children

    Ian F. Pollack

  • Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma

    Nataliya Zhukova;Vijay Ramaswamy;Marc Remke;Elke Pfaff

  • Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma

    Paul A. Northcott;Yukiko Nakahara;Xiaochong Wu;Lars Feuk

  • Mutism and Pseudobulbar Symptoms after Resection of Posterior Fossa Tumors in Children: Incidence and Pathophysiology

    Ian F. Pollack;Paul Polinko;Leland A. Albright;Richard Towbin

  • Intracranial ependymomas of childhood: long-term outcome and prognostic factors.

    Ian Pollack;Peter Gerszten;A. Martinez;Kim-Hung Lo

  • Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group

    Joann L. Ater;Tianni Zhou;Emiko Holmes;Claire M. Mazewski

  • Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group

    Kenneth J. Cohen;Ian F. Pollack;Tianni Zhou;Allen Buxton

  • Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

    Jason Fangusaro;Arzu Onar-Thomas;Tina Young Poussaint;Shengjie Wu

  • Divergent clonal selection dominates medulloblastoma at recurrence

    A. Sorana Morrissy;Livia Garzia;David J.H. Shih;Scott Zuyderduyn

  • Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

    Eric M. Thompson;Eric M. Thompson;Thomas Hielscher;Eric Bouffet;Marc Remke

  • Spinal cord injury without radiographic abnormality in children--the SCIWORA syndrome.

    Dachling Pang;Ian F. Pollack

  • Cytogenetic Prognostication Within Medulloblastoma Subgroups

    David J.H. Shih;Paul A. Northcott;Marc Remke;Andrey Korshunov

  • Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group

    Kenneth J. Cohen;Richard L. Heideman;Tianni Zhou;Emiko J. Holmes

  • Low-grade gliomas of the cerebral hemispheres in children : an analysis of 71 cases

    Ian F. Pollack;Diana Claassen;Qasim Al-Shboul;Janine E. Janosky

  • Expression of p53 and prognosis in children with malignant gliomas.

    Ian F. Pollack;Sydney D. Finkelstein;Jeffrey Woods;Judith Burnham

  • A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study

    Anuradha Banerjee;Regina I. Jakacki;Arzu Onar-Thomas;Shengjie Wu

Frequent Co-Authors

Hideho Okada
Hideho Okada University of California, San Francisco
Ronald L. Hamilton
Ronald L. Hamilton University of Pittsburgh
Roger J. Packer
Roger J. Packer Children’s National Health System
James M. Boyett
James M. Boyett St. Jude Children's Research Hospital
Larry E. Kun
Larry E. Kun St. Jude Children's Research Hospital
Jonathan L. Finlay
Jonathan L. Finlay Nationwide Children's Hospital
Peter C. Burger
Peter C. Burger Johns Hopkins University
Amar Gajjar
Amar Gajjar St. Jude Children's Research Hospital
Michael D. Prados
Michael D. Prados University of California, San Francisco
James M. Olson
James M. Olson Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering studying Medicine in the USA, there are a variety of online degrees and career pathways available that align with healthcare professions. Many students opt for alternative programs to build experience, enhance their credentials, or explore healthcare careers beyond becoming a physician.

For those interested in the administrative side of healthcare, healthcare administration degrees offer the opportunity to work in leadership and management roles within hospitals or clinics. If you prefer direct patient care, nursing is a rewarding track. Some nursing schools that don't require teas or hesi make the admissions process more accessible and less stressful for applicants.

Looking to bridge your current nursing credentials? Explore programs such as adn to np, which allow licensed RNs to become nurse practitioners with advanced degrees. Alternatively, for those interested in a technical, office-based role, there are approved medical billing and coding online schools that accept financial aid, making it easier to start a healthcare career without clinical responsibilities.

Exploring these online options can be an excellent way to launch or advance your healthcare career while balancing other commitments.

Best Scientists Citing Ian F. Pollack

Trending Scientists

Recently Published Articles